Genomic Analysis of Blood and Tumor Samples in Patients With Rare or Poor Prognosis Cancers to Guide Targeted Treatment

What this Trial Is About

Researchers are studying targeted genomic analysis of blood and tissue samples from patients with cancer, focusing on rare cancers with poor prognosis or limited treatment options. This observational research aims to identify genetic changes using genomic sequencing to help understand cancer development and to provide clinicians with mutation data that may guide treatment or referral to relevant studies. The study also collects clinical outcomes and tumor genome data for future analysis and cancer model development. The study involves analyzing previously collected tumor tissue samples using next-generation sequencing to detect mutations. Patients may also provide blood samples for analysis of circulating cell-free DNA and circulating tumor cells. These procedures support the identification of actionable mutations that may have available targeted therapies. The research includes correlative laboratory biomarker analysis. Participants are followed after study completion every 3 months for 2 years, then every 6 months for up to 15 years to monitor clinical outcomes and mutation frequencies. Researchers measure the frequency of specific mutations and the rate of actionable mutations in rare or poor prognosis cancers over this period. This long-term follow-up helps correlate genomic findings with patient outcomes and supports future research developments.

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer